Evaluation of clinical efficacy of comprehensive Chinese and Western medicine in the treatment of acute respiratory distress syndrome

注册号:

Registration number:

ITMCTR1900002296

最近更新日期:

Date of Last Refreshed on:

2019-04-22

注册时间:

Date of Registration:

2019-04-22

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

中西医结合综合方案治疗急性呼吸窘迫综合征的临床疗效评价研究

Public title:

Evaluation of clinical efficacy of comprehensive Chinese and Western medicine in the treatment of acute respiratory distress syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中西医结合综合方案治疗急性呼吸窘迫综合征的临床疗效评价研究

Scientific title:

Evaluation of clinical efficacy of comprehensive Chinese and Western medicine in the treatment of acute respiratory distress syndrome

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900022693 ; ChiMCTR1900002296

申请注册联系人:

张松

研究负责人:

张松

Applicant:

Song Zhang

Study leader:

Song Zhang

申请注册联系人电话:

Applicant telephone:

+86 13880911582

研究负责人电话:

Study leader's telephone:

+86 13880911582

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Zhangyuer2000@163.com

研究负责人电子邮件:

Study leader's E-mail:

Zhangyuer2000@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

成都市金牛区十二桥路39号

研究负责人通讯地址:

成都市金牛区十二桥路39号

Applicant address:

39 Twelve Bridge Road, Jinniu District, Chengdu

Study leader's address:

39 Twelve Bridge Road, Jinniu District, Chengdu

申请注册联系人邮政编码:

Applicant postcode:

610075

研究负责人邮政编码:

Study leader's postcode:

610075

申请人所在单位:

成都中医药大学附属医院

Applicant's institution:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2018KL-070

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

四川中医药区域伦理审查委员会/成都中医药大学附属医院伦理委员会

Name of the ethic committee:

Sichuan Traditional Chinese Medicine Regional Ethics Review Committee / Ethics Committee of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2018/8/23 0:00:00

伦理委员会联系人:

罗晓琼

Contact Name of the ethic committee:

Xiaoqiong Luo

伦理委员会联系地址:

成都市金牛区十二桥路39号

Contact Address of the ethic committee:

39 Twelve Bridge Road, Jinniu District, Chengdu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 028-87783142

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学附属医院

Primary sponsor:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

成都市金牛区十二桥路39号

Primary sponsor's address:

39 Twelve Bridge Road, Jinniu District, Chengdu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

具体地址:

金牛区十二桥路39号

Institution
hospital:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Address:

39 Twelve Bridge Road, Jinniu District

经费或物资来源:

四川省科技厅

Source(s) of funding:

Sichuan Science and Technology Department

研究疾病:

急性呼吸窘迫综合征

研究疾病代码:

Target disease:

Acute respiratory distress syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评价中西医结合综合方案治疗急性呼吸窘迫综合征的临床疗效,为临床治疗提供科学依据。

Objectives of Study:

To evaluate the clinical efficacy of integrated Chinese and Western medicine in the treatment of acute respiratory distress syndrome, and provide a scientific basis for clinical treatment.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 签署知情同意书; ② 符合ARDS的诊断标准; ③ 符合中医辨证分型标准; ④ 年龄大于20岁且小于70岁的患者。

Inclusion criteria

1 Signed informed consent; 2 meets the diagnostic criteria of ARDS; 3 in line with TCM syndrome differentiation criteria; 4 patients aged older than 20 years and less than 70 years.

排除标准:

① 妊娠期或哺乳期妇女; ② 对方案中使用的药物过敏者; ③ 合并有肝肾、造血系统、代谢内分泌系统等严重疾病导致器官功能不全的患者。

Exclusion criteria:

1 pregnant or lactating women. 2 those who are allergic to the drugs used in the program. 3 patients with liver and kidney, hematopoietic system, metabolic endocrine system and other serious diseases leading to organ dysfunction.

研究实施时间:

Study execute time:

From 2018-01-01

To      2019-12-30

征募观察对象时间:

Recruiting time:

From 2018-07-01

To      2020-12-31

干预措施:

Interventions:

组别:

治疗组

样本量:

55

Group:

Therapy group

Sample size:

干预措施:

在西医综合治疗的基础上加用加味潜阳丹

干预措施代码:

Intervention:

Adding Jiawei Qian-Yang Dan on the basis of comprehensive treatment of Western medicine

Intervention code:

组别:

对照组

样本量:

55

Group:

Control group

Sample size:

干预措施:

西医综合治疗+安慰剂

干预措施代码:

Intervention:

Western medicine comprehensive treatment + placebo

Intervention code:

样本总量 Total sample size : 110

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

眉山

Country:

China

Province:

Sichuan

City:

Meishan

单位(医院):

眉山市中医医院

单位级别:

三级甲等

Institution/hospital:

Meishan Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川

市(区县):

内江

Country:

China

Province:

Sichuan

City:

Neijiang

单位(医院):

内江市第二人民医院

单位级别:

三级甲等

Institution/hospital:

Neijiang Second People Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

四川

市(区县):

遂宁

Country:

China

Province:

Sichuan

City:

Suining

单位(医院):

遂宁市中医院

单位级别:

三级甲等

Institution/hospital:

Suining Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

中医证候积分

指标类型:

主要指标

Outcome:

Type:

Primary indicator

测量时间点:

TCM syndrome points

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管外肺水指数

指标类型:

主要指标

Outcome:

Extravascular lung water index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

28天病死率

指标类型:

主要指标

Outcome:

28-day mortality rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸部影像学

指标类型:

主要指标

Outcome:

Chest imaging

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

机械通气时间

指标类型:

主要指标

Outcome:

Mechanical ventilation time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU住院时间

指标类型:

主要指标

Outcome:

ICU hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧合指数

指标类型:

主要指标

Outcome:

Oxygenation index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

动脉血、静脉血

组织:

Sample Name:

Arterial blood, Venous blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由刘清海医师利用SAS软件中的随机数字生成器。

Randomization Procedure (please state who generates the random number sequence and by what method):

Utilize random number generators in SAS software.

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2020.07.01 ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2020.07.01 ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者需根据研究方案要求把收集的数据填入病例报告表。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Researchers need to fill in the collected data to the case report form according to the requirements of the research program.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above